Please login to the form below

Not currently logged in
Email:
Password:

mergers

This page shows the latest mergers news and features for those working in and with pharma, biotech and healthcare.

Takeda rebels take aim at Shire acquisition

Takeda rebels take aim at Shire acquisition

Takeda rebels take aim at Shire acquisition. Opposition to Takeda’s yet-to-be-finalised $63bn takeover of Shire appears to be building among some shareholders in Japan. A small but increasingly vocal group of rebel investors – including members

Latest news

More from news
Approximately 85 fully matching, plus 437 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 73 fully matching, plus 38 partially matching documents found.

Latest appointments

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    With expertise in corporate partnering, mergers and acquisitions, pipeline and product portfolio development, legal and IP strategy, Magovcevic-Liebisch has worked in several management roles including executive vice president and chief

  • IRX Therapeutics appoints Luba Greenwood to its board IRX Therapeutics appoints Luba Greenwood to its board

    Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations. ... Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

  • Reig Jofre boosts Forté Pharma’s senior team Reig Jofre boosts Forté Pharma’s senior team

    Ignasi Biosca, chief executive officer, Reig Jofre, said: “We had been working for some time on Forté Pharma's development plan after the merger with Natraceutical, and I am convinced that

  • Reig Jofre appoints Alejandro Reig as vice president Reig Jofre appoints Alejandro Reig as vice president

    He most recently took the director position at Reig Jofre after its merger with Natraceutical in December 2015.

  • Apeiron bolsters management board Apeiron bolsters management board

    With more than 25 years’experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently

More from appointments
Approximately 0 fully matching, plus 49 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics